CD274 and non-small cell lung carcinoma: Furthermore, PD-L1 (CD274) was differentially expressed between patients receiving 1 L and ≥2 L ICI, which correspond to the different PD-L1 cut-offs in treatment guidelines in patients with advanced NSCLC [9].